Nominations for the plc awards 2021 are now open! See the 2021 award categories and criteria here.

Less Ads, More Data, More Tools Register for FREE

Open Orphan pharma spin-out Poolbeg Pharma present at London South East's October live event


We were delighted to welcome Jeremy Skillington and Cathal Friel, CEO and Chairman at Open-Orphan (ORPH) spin-out Poolbeg Pharma (POLB), an infectious diseases specialist.

In July Poolbeg Pharma IPO'd on AIM, raising £25M, a pot of money which the team intend to use to develop 5 or 6 core assets which can then be sold on to Big Pharma companies.

The company has already inherited a Phase II ready influenza immune-modulater, and says it hopes to acquire new assets and licences.

Watch out for acquisition announcements in the weeks and months ahead say the company.

Poolbeg is targeting the infectious diseases market, which is expected to exceed $250 bn dollars by 2025. POLB’s initial assets come from Open Orphan, the infectious disease and human challenge trials business, which means Poolbeg has access to knowledge, experience and clinical data from 20 years of clinical challenge trials.

This webinar event was sponsored by PrimaryBid. The best way to hear about their offers is to register on their website at primarybid.com.

Latest Media

What's Hot in the Omicron Universe

AIM Fintech Glantus Holdings successfully rolling out buy & build strategy says CEO Maurice Healy

Zenith Energy purchase 22.5% stake in Tunisian SLK concession from CNPC for $1.65M

Related Shares

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.